Australia Markets close in 3 hrs 35 mins

Histogen Inc. (HSTO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2800-0.0400 (-1.72%)
At close: 04:00PM EDT
2.2500 -0.03 (-1.32%)
After hours: 06:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.3200
Open2.1900
Bid2.0500 x 1100
Ask2.3700 x 1100
Day's range2.1700 - 2.3000
52-week range2.0600 - 22.2000
Volume28,233
Avg. volume163,867
Market cap113.886M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.4930
Earnings date09 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.25
  • GlobeNewswire

    Histogen Announces 1-for-20 Reverse Stock Split

    SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s issued and outstanding common stock (the “Reverse Stock Split”). The Reverse Stock Split will be effective at 4:01 p.

  • GlobeNewswire

    Histogen to Present at the H.C. Wainwright Global Investment Conference

    SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen’s Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference. On-Demand Presentation DetailsD

  • GlobeNewswire

    Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

    Received $3.75 Million Payment from Allergan Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee Ongoing with Top-Line Data Anticipated in the First Half of 2023 SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the first